Unicycive Therapeutics to Present Kidney Disease Therapies at Investment Conference

LOS ALTOS, Calif., Sept. 01, 2026 /CourierPR/ -- Unicycive Therapeutics, a clinical-stage biotechnology company focused on developing therapies for kidney diseases, will present its latest advancements at the H.C. Wainwright 28th Annual Global Investment Conference. The company's chief executive officer, Dr. Shalabh Gupta, will deliver the presentation on Tuesday, September 15, 2026, at 11 a.m. Eastern Time.

Unicycive is currently working on several novel treatments, with its lead investigational therapy, oxylanthanum carbonate, a key focus. This drug is designed to address hyperphosphatemia, a condition common in patients with chronic kidney disease who are undergoing dialysis. The company’s second investigational treatment, UNI-494, is aimed at treating conditions related to acute kidney injury and has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for preventing Delayed Graft Function (DGF) in kidney transplant patients. UNI-494 has also completed a Phase 1 safety study in healthy volunteers.

For those interested in following the presentation, a live and archived webcast will be available on Unicycive’s website under the Investors section, Events and Presentations. The company has also provided details on its treatments and ongoing research through its website, LinkedIn, and X social media platforms.

Unicycive Therapeutics, Inc., continues to advance its mission to improve patient outcomes in kidney disease through innovative therapies. The company’s latest developments are expected to play a crucial role in the broader discussions at the investment conference, offering insights into potential future treatments and advancements in the field of nephrology.